TRP.AU Tissue Repair Ltd
- Market cap
- AUD 5.06M
- P/E
- -
- P/B
- 0.65x
- ROE
- -61.1%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is TRP.AU undervalued?
Graham numberThe Graham number of Tissue Repair Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tissue Repair Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-61.1%), below 10%.
ROA 0/1
Return on assets (-51.8%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-26.5%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 466.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.7x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Tissue Repair Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous le…
Full company profileTissue Repair Ltd financial statements
Tissue Repair Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 156.00 | 153K | 172K | 3.08K | 152K | 2.63M | 560K |
| Gross Profit | - | 156.00 | 153K | 170K | 428.00 | 151K | 2.63M | -1.80M |
| Operating Income | -557K | -449K | -640K | -4.23M | -5.74M | -6.52M | -4.72M | -7.98M |
| EBITDA | - | -52.2K | -189K | -7.01M | -5.14M | -6.51M | -4.72M | -7.75M |
| Net Income | -357K | -352K | -915K | -6.84M | -4.17M | -4.14M | -4.24M | -5.36M |
| EPS | - | -0.01 | -0.02 | -0.11 | -0.07 | -0.07 | -0.07 | -0.09 |
| Balance Sheet | ||||||||
| Total Assets | - | 1.33M | 27.6M | 25.9M | 22.4M | 19.4M | 14.6M | 10.3M |
| Total Liabilities | - | 329K | 536K | 560K | 497K | 1.35M | 663K | 1.57M |
| Shareholders' Equity | - | 1,000K | 27.1M | 25.3M | 21.9M | 18.0M | 13.9M | 8.77M |
| Cash & Short-term Investments | - | 1.15M | 27.1M | 25.5M | 21.4M | 16.4M | 12.3M | 4.77M |
| Total Debt | - | - | 7.50M | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | - | -650K | -853K | -3.97M | -4.26M | -4.95M | -3.70M | -7.50M |
| Capital Expenditure | - | 3.92K | 3.92K | 3.92K | 2.24K | 3.36K | 422K | 43.6K |
| Free Cash Flow | - | -650K | -853K | -3.97M | -4.26M | -4.95M | -4.12M | -7.55M |
| Ratios | ||||||||
| ROE | - | -35.2% | -3.4% | -27.0% | -19.1% | -22.9% | -30.5% | -61.1% |
| ROA | - | -26.5% | -3.3% | -26.4% | -18.7% | -21.3% | -29.1% | -51.8% |
| Net Profit Margin | - | -225,778.2% | -599.6% | -3,977.2% | -135,709.1% | -2,718.1% | -161.0% | -958.0% |
| Debt to Equity | - | - | 0.28x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tissue Repair Ltd dividends
Tissue Repair Ltd has not paid dividends in the last 7 fiscal years.
Who owns Tissue Repair Ltd
- Insiders 55.26%
- Institutions 0.00%
- Public & others 44.74%
- Shares outstanding 53.3M
- Free float 34.4M
Tissue Repair Ltd company profile
- Company name
- Tissue Repair Ltd
- Ticker
- TRP.AU
- ISIN
- AU0000180887
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Tower A, The Zenith, Chatswood, NSW, Australia, 2067
- Phone
- 61 4 2798 5805
- Website
- tissuerepair.com.au
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.
Tissue Repair Ltd management
5- Mr. Tony ChararaCo-Founder, CEO & Executive Director
- Mr. Peter D. A. Scutt BComCo-Founder & Executive Director
- Mr. Mark Wouter BouwChief Financial Officer
- Dr. Sarika NamjoshiChief Operating Officer
- Ms. Sushma KejriwalCompany Secretary